Point-of-care coagulation testing in patients suffering from COVID-19

Point-of-care coagulation testing in patients suffering from COVID-19 - CLOT-III

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00021255

Enrollment

Registered

2020-04-28

Start date

2020-05-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1 J80

Interventions

Group 1: The blood coagulation of patients with COVID-19, who are in need of intensive care, is examined once a day using thrombelastometry and impedance aggregometry. The examinations are carried out

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patient suffering from COVID-19 in the need for critical care Age > 17 years Informed consent of either the patient or an independent physician and the relatives / legal caregiver

Exclusion criteria

Exclusion criteria: Age < 18 years Refuse to participate Not in the need for critical care

Design outcomes

Primary

Measure	Time frame
Correlation of the cumulative 7-day amplitude of the thrombelastometric measurements of native blood (NATEM) and the 30-day mortality. The maximum amplitudes (MCF, maximum clot firmness) of the daily thromlastometric measurements of the native blood (NATEM) are summed up. In the case of a homogeneous distribution, a correlation with the 30-day mortality is carried out. In the case of a multi-peak distribution, groups should be defined and their survival times analyzed.	—

Measure

Time frame

Correlation of the cumulative 7-day amplitude of the thrombelastometric measurements of native blood (NATEM) and the 30-day mortality. The maximum amplitudes (MCF, maximum clot firmness) of the daily thromlastometric measurements of the native blood (NATEM) are summed up. In the case of a homogeneous distribution, a correlation with the 30-day mortality is carried out. In the case of a multi-peak distribution, groups should be defined and their survival times analyzed.

—

Secondary

Measure	Time frame
The correlation between cumulative blood coagulability in the first 7 days after admission to the intensive care unit and the ventilation-free days on the intensive care unit is the secondary outcome. See detailed procedure for the primary endpoint.	—

Countries

Germany

Contacts

Public ContactUlrich Limper

Klinik für Anästhesiologie und operative IntensivmedizinKlinikum Köln-MerheimKliniken der Stadt Köln gGmbH

limperu@kliniken-koeln.de022189073863

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026